Sheila Gujrathi (Gossamer Bio)

Gos­samer shares take an­oth­er beat­ing as its lead drug fails 2 key clin­i­cal stud­ies, high­light­ing harsh re­views for DP2

Ever since a key DP2 drug at No­var­tis called fe­vip­iprant failed a piv­otal line­up of clin­i­cal stud­ies by the end of last year, a num­ber of an­a­lysts have been sit­ting back wait­ing to see how the same kind of drug would fare at Gos­samer.

Tues­day morn­ing they found out, and it wasn’t pret­ty.

The biotech says their lead drug GB001 failed the pri­ma­ry end­point in their dose-rang­ing asth­ma study as well as all the end­points in a par­al­lel tri­al they ran for chron­ic rhi­nos­i­nusi­tis.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.